The Charles Tate most likely to appear in a net worth search is Charles W. Tate, the Houston-based private equity investor who founded Capital Royalty Group (CRG), a healthcare-focused investment firm. Based on publicly available signals, including SEC beneficial ownership filings, fund disclosures, and press coverage of CRG's scale, a reasonable estimated net worth range for Charles W. Tate sits somewhere between $200 million and $500 million as of mid-2026, though no single verified figure exists in the public record. That wide range reflects the nature of private equity wealth: most of it lives in fund stakes and carried interest that are never disclosed in full detail.
Charles Tate Net Worth: Estimates, Assets, and Income Breakdown
Marcus Redfield
5 May 2026
Which Charles Tate are we talking about?
"Charles Tate" is not a uniquely identifying name, so it is worth being upfront about who this article covers. Multiple individuals carry this name, and low-authority net worth sites often conflate them or assign figures without any sourcing. The Charles Tate with the most documented financial footprint is Charles W. Tate of Houston, Texas. He appears in SEC filings as the sole and managing member of Capital Royalty, he is identified by Forbes as a Texas investor and former partner at Hicks, Muse, Tate & Furst, and he is named by the Houston Business Journal and PR Newswire as the founder of CRG LP (also known as Capital Royalty Group). This is the person this article is about. If you are searching for a different Charles Tate in entertainment, sports, or another field, the financial profile here will not apply to them.
Current estimated net worth range
No verified, timestamped net worth figure for Charles W. Tate exists in public records as of May 2026. What does exist are several reliable data points that allow for a credible range estimate. If you are specifically looking for the current estimate, Charles Tate's net worth is commonly reported in a $200 million to $500 million range based on the public signals discussed here matthew charles labyorteaux net worth. CRG launched an $805 million fund strategy as early as 2013, according to Fierce Biotech. SEC filings confirm Charles Tate as the beneficial owner of shares held across multiple Capital Royalty entities (Capital Royalty Partners, Capital Royalty Parallel, and related vehicles). Forbes identified him in the context of documented philanthropy typical of individuals with nine-figure wealth. Taking into account fund management economics, his likely carried interest stakes, and the long operating runway of CRG, a $200 million to $500 million range is the most defensible estimate available right now.
The lower bound reflects a conservative reading where fund returns were modest and a large portion of capital was reinvested rather than distributed. The upper bound reflects a scenario where carried interest from multiple fund vintages compounded over a decade-plus career. Without a public company filing, a divorce proceeding, a political financial disclosure, or similar primary document, pinning the number more tightly is not possible with integrity.
How the money was made: career earnings breakdown
Hicks, Muse, Tate & Furst (pre-CRG)
Charles Tate spent a significant portion of his career as a partner at Hicks, Muse, Tate & Furst, a high-profile Dallas-based leveraged buyout firm active through the 1990s and early 2000s. Forbes noted this background explicitly. Partners at that firm participated in the economics of deals that spanned media, telecom, and other sectors. Even if only a fraction of those returns flowed to Tate personally, the years at Hicks Muse would have been a foundational wealth-building period, providing the capital base and industry relationships he later used to launch CRG.
Capital Royalty Group (CRG): the primary wealth engine
CRG is a Houston-based healthcare and life sciences private equity firm specializing in royalty monetization and debt financing for biotech and pharmaceutical companies. Charles Tate founded it and served as Chairman until stepping down from day-to-day operations on March 31, 2018, at which point he became Chairman Emeritus, according to a PR Newswire announcement. The firm's 2013 fund strategy alone targeted $805 million in deployable capital. As founder and managing member, Tate would have held a meaningful management fee percentage (typically 1.5 to 2 percent of committed capital annually) plus carried interest (typically 20 percent of profits above a hurdle rate). Over multiple fund cycles spanning roughly 2009 to 2018, those economics can produce substantial wealth even before accounting for any personal co-investment returns.
Assets, income streams, and financial holdings
Because Charles W. Tate is a private individual managing private funds, his asset disclosure is minimal. However, the publicly documented pieces of his financial picture include the following:
- Beneficial ownership of shares in portfolio companies held through Capital Royalty Partners and Capital Royalty Parallel entities, as documented in SEC Schedule 13D and 13G filings
- Carried interest stakes across CRG fund vintages, the value of which depends on portfolio company performance and exit timing
- Management fee income earned during his active tenure running CRG (2009 to 2018, approximately)
- Likely personal co-investments in CRG portfolio companies, standard practice for fund managers
- Philanthropic activity documented by Forbes, suggesting liquid assets sufficient to fund significant charitable giving
- Real estate holdings in Houston are plausible given his profile and tenure in the city, but no specific properties are publicly confirmed
Since transitioning to Chairman Emeritus status, active management fee income has likely decreased or ceased. However, carried interest distributions from funds raised during his active tenure would still flow to him as deals are exited, meaning his wealth continues to compound passively even after stepping back from operations.
Legal and financial history that affects the estimate
No significant litigation, regulatory action, enforcement proceeding, or public financial distress related to Charles W. Tate has surfaced in the documented public record available as of May 2026. His SEC filings reflect standard beneficial ownership disclosures tied to fund management activity, not enforcement actions. The Houston Business Journal's coverage of his 2018 leadership transition at CRG described it as a planned, orderly succession rather than a forced departure. This matters for wealth estimates because the absence of adverse legal history means there is no documented basis for a significant downward revision due to settlements, judgments, or forced asset sales.
That said, private equity returns are not immune to market cycles. Healthcare royalty and biotech debt funds can underperform if portfolio companies fail to achieve milestones or if drug approvals are delayed. If CRG fund vintages had lower-than-expected returns, carried interest distributions would be correspondingly lower. This is the most plausible mechanism by which the real number could sit closer to the lower bound of the $200 million to $500 million range than the upper.
How net worth is calculated here, and how to read these estimates
Net worth is assets minus liabilities. For a private equity professional like Charles Tate, the hardest part is valuing the assets, not finding the liabilities. The methodology used to arrive at the estimate in this article works as follows:
- Identify confirmed primary income sources: SEC filings, press coverage, and corporate bios establish CRG fund management and carried interest as the core earnings mechanism
- Estimate fund economics: publicly reported fund sizes (the $805M 2013 strategy is the clearest data point) are used to model plausible management fee revenue and carried interest, applying industry-standard terms
- Anchor with comparable wealth signals: Forbes coverage and documented philanthropy suggest high-net-worth status consistent with a nine-figure range
- Apply a confidence discount: because no primary financial disclosure (tax returns, political filings, court documents) exists, a wide range is used rather than a single number to reflect genuine uncertainty
- Flag liabilities as unknown: personal debt, real estate mortgages, and business liabilities are not publicly documented, so the estimate assumes a net positive position without claiming precision
If you want to check for updates or sharper estimates, the most productive places to look are SEC EDGAR (search for Capital Royalty beneficial ownership filings), Texas public records for real estate, and any political donor disclosures if Tate has made federal contributions above the reporting threshold. Those sources tend to surface faster than third-party net worth aggregators, most of which recycle each other's figures without original sourcing.
Putting the number in context
A $200 million to $500 million range for a founder of a multi-hundred-million-dollar healthcare private equity firm with a prior career at a major leveraged buyout shop is internally consistent and not extraordinary for that profile. It is a meaningfully different financial situation from other notable Charles figures in related research, such as those in entertainment or music, where wealth tends to be more concentrated in royalties, catalog valuations, and performance income rather than fund economics and carried interest. The methodology and evidence quality for Charles W. Tate's estimate is stronger than most celebrity net worth figures precisely because SEC filings and institutional press coverage leave a more traceable paper trail than entertainment industry deals. You can also search for the latest figures for Matthew Charles Sanders net worth to compare how different public profiles and sourcing affect estimates more traceable paper trail.
| Factor | Assessment | Impact on Estimate |
|---|---|---|
| Primary income source | CRG fund management fees and carried interest | High positive |
| Career history | Hicks, Muse, Tate & Furst partner pre-CRG | Moderate positive (foundational capital) |
| Fund scale | $805M+ strategy documented as of 2013 | Supports upper range |
| Public disclosure level | Private individual, no political/court filings found | Wide confidence interval |
| Legal/financial risk factors | None documented in public record | No downward revision warranted |
| Post-retirement income | Carried interest distributions likely ongoing | Sustains or grows current estimate |
FAQ
How can I tell which Charles Tate the net worth results are referring to?
Look for Houston, Texas ties and Capital Royalty Group (CRG) or Capital Royalty entity names. If the profile mentions a different industry (sports, entertainment) or lacks any CRG/Capital Royalty context, it is likely a different person. Name-only searches are a common source of mistaken identity.
Why is Charles Tate’s net worth reported as a wide range instead of a single number?
Because a private equity founder’s real wealth is largely in fund interests and carried interest, which are not fully itemized publicly. Without a primary document that states asset values and liabilities (for example, a verified personal balance sheet), any single figure would be guesswork rather than an evidence-based estimate.
Does stepping down as day-to-day Chairman Emeritus in 2018 mean his income stopped?
Not necessarily. Even if active management fees decline, carried interest distributions can still come in later as underlying deals are exited. Your best mental model is that wealth can continue to grow through distributions and compounding even after reduced operational involvement.
What is the biggest driver of the high end of the $200 million to $500 million estimate?
Compounding across multiple fund vintages where returns exceeded hurdle rates, generating carried interest over time. The high end assumes both strong deal outcomes and that a meaningful portion of profits translated into distributions to him personally rather than being reinvested or allocated elsewhere.
What would push the estimate closer to the lower bound?
Underperformance in healthcare royalty or biotech debt portfolios, delays in clinical or approval milestones, or repayment failures that reduce fund profits. If fewer deals generate the profit needed for carried interest, the personal upside shrinks even if the firm remains operational.
Are SEC beneficial ownership filings enough to compute net worth precisely?
They help confirm ownership and track holdings, but they usually do not provide the full economic value. Public filings may show who owns which shares or entities, yet they often do not disclose the total fair value of fund stakes or the extent of liabilities, so they support ranges rather than exact totals.
Does Charles Tate’s prior career at Hicks, Muse, Tate & Furst change the estimate materially?
It can provide a plausible starting capital base and early industry exposure, but it is not directly quantifiable from public data in a way that tightens the current range. The article’s estimate mainly relies on CRG economics and documented fund scale rather than trying to back-calculate historical payouts from the earlier firm.
How reliable are third-party net worth aggregator sites for this specific query?
They tend to be lower reliability when multiple people share the same name or when they reuse each other’s numbers without original sourcing. For Charles W. Tate specifically, higher authority checks are SEC EDGAR, relevant Texas public records, and donor disclosures, where available.
If I want a fresher number than mid-2026, what should I check first?
Start with SEC EDGAR for Capital Royalty beneficial ownership updates, then look for Texas property records tied to his name and related entities. If he has federal political contributions above the reporting threshold, donor disclosures can also provide indirect confirmation of wealth scale.
Could there be hidden liabilities that make the range inaccurate?
Possibly, but there is no documented public evidence of major litigation, enforcement actions, or financial distress in the record discussed. The bigger uncertainty is typically asset valuation for private fund interests, not known liabilities, which is why the estimate stays broad.